Skip to main content
Equibles
DTIL logo

DTIL · Precision Biosciences Inc

Track DTIL — free

Use DTIL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$7.47 +0.10 (+1.36%) At close · Sep 4
Russell 2000 member Rebalance outlook locked
Market Cap
$206.18M
Shares
27.60M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.47 Open$7.32 Day$7.32–7.58 52W close$3.57–9.28 Avg vol 30d269K Short int2.4M · 8.7% float · 9.1d Short vol61% Last earningsFeb 11, 2026 DataFeb 2024–Sep 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Feb 14, 2024; bars on opposite sides are not compared.

Up next

Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$45.05M
Trailing 12 months
Net income (TTM)
−$52.73M
Trailing 12 months
Revenue growth YoY
-50.1%
Year over year
Operating margin
-80.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-25.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+86.3%
Year over year · more shares
Price change (1Y)
+48.5%
Trailing year
Short interest
8.7%
Latest settlement · 9.1 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +21%
above
Price vs 50-day avg −5%
below
RSI (14) 43
neutral
MACD trend Negative
52-week position 68%
mid-range
Momentum
relative strength
Very Strong
1-month return 0%
trailing
6-month return +19%
trailing
YTD return +80%
this year
Relative strength +3%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+23% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.70% of float · ▼ -16.6% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Squeeze score 60
elevated · 0–100
Fundamentals
Fair
EPS growth −442%
Y/Y
Balance sheet $167.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −59%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+21% Bullish
Price vs 50-day avg
−5% Neutral
RSI (14)
43 Neutral
MACD trend
Negative Bearish
52-week position
68% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $8 › 200d $6 — 50d above 200d
Institutional flow Accumulating
+23% holders QoQ · +31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.70% of float · ▼ -16.6% MoM · 9.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $7 · 68% Range high $9
vs 200-day avg +21% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DTIL
Precision Biosciences Inc
this stock
$206.18M +79.6% +41.0% — 8.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.42B +20.5% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.22B +7.2% +20.8% 20.5 2.3%
ARGX
Argenx SE
 $64.25B +22.9% — — 1.9%
CSLLY
Csl Ltd
 $60.55B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
96
% held
64.1%
Net QoQ
+1.5M sh
Top holder
Aberdeen Group plc
Held Float
View
Held by Funds
Fund positions
68
View
Short & Settlement
Short Interest Falling
Shares short
2.4M
Days to cover
9.1d
Change
-477.0K sh
View
Short Volume
Short vol %
61%
As of
Sep 4, 2026
Short Total
View
Fails to Deliver
FTD shares
5.1K
Value
$37.2K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
42.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$34.3M
Net income (FY)
$-45.7M
EPS diluted
$-3.56
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 24, 2026
This year
18
View
Proposed Sales
Value
$79.0K
Shares
20.6K
Filed
Feb 18, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 3, 2026
View

Performance

Raw-price comparisons begin at the captured split on Feb 14, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
DTIL -4.0% -0.3% +18.6% -2.2% +79.6%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -4.1% +0.1% +3.5% -2.6% +66.6%
Key facts CIK 1357874 CUSIP 74019P207 13F (30d) 75 filings 75 filers Visit website Investor relations